You just read:

Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy

News provided by

Trovagene, Inc.

Aug 16, 2017, 08:00 ET